CJC-1295 With DAC vs Sermorelin: Research Comparison
A Side-By-Side Research Comparison Of CJC-1295 With DAC And Sermorelin - a long-acting versus a short-acting GHRH analog. This Reference Compares Mechanism, Evidence Tier, Molecular Identity, And Pharmacokinetics For Qualified Researchers. For In Vitro Laboratory Research Use Only. Not Medical Advice Or Dosing Guidance.
Side-By-Side Comparison
| CJC-1295 With DAC | Sermorelin | |
|---|---|---|
| Category | Muscle Growth & Performance | Muscle Growth & Performance |
| Compound Class | Long-acting synthetic GHRH analog with Drug Affinity Complex (DAC) albumin-binding moiety | Synthetic 29-amino acid fragment of endogenous GHRH (GHRH 1-29-NH2) |
| Evidence Tier | Research Compound | Approved Drug |
| Molecular Target | GHRH receptor (GHRHR) on pituitary somatotrophs; sustained GH and IGF-1 elevation | GHRH receptor (GHRHR) on anterior pituitary somatotrophs; stimulates endogenous GH gene expression and release |
| Molecular Weight | 3647.1 Da | 3357.93 Da |
| Amino Acid Sequence | tetrasubstituted GRF(1-29) + DAC | GHRH(1-29) amide |
| CAS Number | 446262-90-4 | 86168-78-7 |
| Half-Life | ~6-8 days (albumin-bound, DAC) | ~10-20 min |
| Studied For | GH pulsatile release research, GH-axis anti-aging, Growth hormone deficiency, Extended GH secretion | Pituitary GH-reserve diagnostic, Pediatric GH deficiency (historical), Adult GH-axis / anti-aging research, GH secretagogue research |
About CJC-1295 With DAC
A long-acting growth-hormone-releasing peptide; banned in sport.
Read The Full CJC-1295 With DAC MonographAbout Sermorelin
A growth-hormone-releasing hormone analog formerly approved for childhood GH deficiency; banned in sport.
Read The Full Sermorelin MonographKey Differences
- Evidence tier differs: CJC-1295 With DAC is classified as Research Compound; Sermorelin is classified as Approved Drug.
- Reported half-life differs: CJC-1295 With DAC at ~6-8 days (albumin-bound, DAC) versus Sermorelin at ~10-20 min.
- Primary molecular target differs: CJC-1295 With DAC acts on GHRH receptor (GHRHR) on pituitary somatotrophs; sustained GH and IGF-1 elevation; Sermorelin acts on GHRH receptor (GHRHR) on anterior pituitary somatotrophs; stimulates endogenous GH gene expression and release.
Continue Researching
CJC-1295 With DAC · Sermorelin · Compare Tool · Research Library
This Comparison Is Provided For In Vitro Laboratory Research Use Only. Not For Human Consumption, Diagnosis, Or Treatment. See The Full Research Disclaimer.